Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

Rubicon Research Limited

NSE: RUBICONPharmaceuticalsASM stage 1

Share price

₹1,535.40

-2.55% close of 8 Oct 2026

Market cap ₹26,102 CrP/E 90.3

Business score

How strong the business is, in one number. The parts behind it are in Pro.

68

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹26,102 Cr

P/E ratio

90.3

P/B ratio

19.7

ROCE

28.4%

ROE

27.0%

Dividend yield

0.1%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 8 Oct 2026 close52-week high ₹1,860.6052-week low ₹577.25

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Fewer than three years of filings — too early to judge growth.

Whether it grew faster than its sector

It grew 40.4% a year against a sector median of 13.1% — 27.3 percentage points faster.

Room to re-rate, or risk of de-rating

Too little price history yet to compare it with its own past.

Whether growth justifies the valuation

Priced at 0.6 times its growth rate, on earnings growth of 155%.

Profit growthPrice per ₹1 profitPer 1% growth
Rubicon Research Limited — this one155%/yr90.3×—
Sun Pharmaceutical13%/yr33.4×₹2.6
Divi's Laboratories13%/yr83.3×₹6.4
Torrent Pharmaceuticals22%/yr78.7×₹3.6
Zydus Lifesciences32%/yr23.1×₹0.72
Laurus Labs Limited4%/yr98.6×₹24.7

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 15 of 130 on returns, 5 of 127 on growth, 42 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

A wide advantage: it earns 28.4% on capital, ahead of 88% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

No — Over the last five years it made ₹247 crore of cash from the business but spent ₹451 crore on plant and equipment, ₹204 crore more than it made; the gap was from lenders and shareholders. And the profit is real: of every 100 rupees it reported over 7 years, about 67 arrived as cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

7 of 9 checks clear · 78%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Revenue grew 52% and profit nearly doubled while margin guidance moved up to 23% for FY27.

Announced 14 Aug 2026 · Consolidated · Unaudited

Revenue

₹534 Cr

Revenue vs last year

+51.8%

Revenue vs last quarter

+4.0%

Net profit

₹85 Cr

Profit vs last year

+97.2%

Profit vs last quarter

+10.1%

Net margin

15.9%

EPS

₹5.13

Earnings call transcript · 14 Aug 2026

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹26,102 Cr
Prev close
₹1,535.40
52w High
₹1,899
52w Low
₹571
Enterprise value
₹26,067 Cr
Beta
0.4
Price CAGR 1y
—
Price CAGR 3y
—
Price CAGR 5y
—
Price CAGR 10y
—

Ratios

Return on assets
10.6%
PEG ratio
0.6
P/E ratio
90.3
P/B ratio
19.7
EV / EBITDA
57.9
Industry P/E
38.0
ROCE
28.4%
ROCE 5y average
12.4%
ROE
27.0%
Debt / Equity
0.2
Interest coverage
8.6
Dividend yield
0.1%
ROE 3y average
27.0%
ROE last year
27.0%

Annual P&L

Annual revenue
₹1,754 Cr
Annual profit
₹247 Cr
Operating margin
23.0%
Net profit margin
14.1%
EBITDA margin
22.8%
Sales growth 3y
64.5%
Sales growth 5y
41.0%
Profit growth 3y
155.0%
Profit growth 5y
52.0%
EPS
₹15.0
Sales growth TTM
47.0%
Profit growth TTM
89.0%
Dividend payout
10.0%

Quarter P&L

Sales latest quarter
₹534 Cr
Profit latest quarter
₹85 Cr
YoY quarterly sales growth
51.6%
YoY quarterly profit growth
97.7%
OPM latest quarter
24.2%

Balance Sheet

Book Value
₹75.8
Face Value
₹1.0
Total debt
₹311 Cr
Total cash
₹346 Cr
Borrowings
₹311 Cr
Reserves / Equity
74.8

Cash Flow

Operating cash flow
₹205 Cr
Free cash flow
-₹24 Cr
FCF yield
-0.3%
Net cash flow
₹81 Cr

Shareholding

Promoter holding
59.8%
FII holding
7.5%
DII holding
9.4%
Public holding
23.3%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,758.8033.44,21,9950.902,901.26.015,299.910.520.5
Divi's Lab.9,434.4084.02,50,4540.31902.065.53,080.027.822.0
Torrent Pharma.4,631.2079.01,76,1560.81566.05.84,921.054.915.2
Zydus Lifesci.1,116.0022.91,11,3210.09990.2-35.18,017.022.021.1
Laurus Labs2,021.5099.91,09,2240.10362.1125.52,026.329.117.8
Cipla1,302.6529.41,05,2370.98785.6-39.27,119.32.315.5
Mankind Pharma2,389.9046.298,7140.04574.129.64,030.612.913.5
Rubicon Research1,537.5588.325,4510.1084.895.8534.351.628.4
Median414.0034.12,1230.0713.529.5164.018.415.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales296313358352412476514534
Expenses234244286273318367395405
Material Cost142184155154
Change in Inventories-37-48-31-7.05
Purchases of Stock-in-Trade21224522
Employee Cost63666886
Other Expenses128144158151
Operating Profit6270727994108119129
OPM %2122202223232324
Other Income30011436
Exceptional items (within Other Income)0000
Interest7812111110109
Depreciation89101012121215
Profit before tax49535160729199110
Tax %3028292725202223
Net Profit3438364354737785
EPS in Rs2.272.502.352.813.494.424.655.13
Diluted EPS in Rs3.474.414.605.08

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales2633153143948541,2841,7541,936
Expenses1822233533756991,0201,3541,486
Material Cost615
Change in Inventories-150
Purchases of Stock-in-Trade91
Employee Cost256
Other Expenses541
Operating Profit8192-3918155264400450
OPM %3129-124.7018212323
Other Income18101725184813
Exceptional items (within Other Income)0
Interest69101931374241
Depreciation1829343639374551
Profit before tax7463-66-11103195321371
Tax %3351253123123
Net Profit4931-67-1791134247288
EPS in Rs9761-132-335.988.721518
Diluted EPS in Rs15
Dividend Payout %22-0-20010

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
—
5 years
41%
3 years
65%
TTM
47%

Compounded profit growth

10 years
—
5 years
52%
3 years
155%
TTM
89%

Return on equity

10 years
—
5 years
16%
3 years
27%
Last year
27%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital5555151517
Reserves3353693002813705261,272
Borrowings3093175320425418311
Other Liabilities607179144300493727
Minority Interest0.00
Total Liabilities4305385607501,1091,4512,327
Fixed Assets157188193199307327532
CWIP2632510741
Investments1914000027
Other Assets2523303645267931,1181,728
Total Assets4305385607501,1091,4512,327

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity562-63-7521159205
Cash from Investing Activity-84-46-46-32-68-65-407
Cash from Financing Activity80526312344-40283
Net Cash Flow167-4516-45481
Free Cash Flow-54-10-117-119-3591-24

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days19415816220912992106
Inventory Days360508502609428574550
Days Payable183271320353252263285
Cash Conversion Cycle371395345465305403371
Working Capital Days183149107755746104
ROCE %17-121192628

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemDec 2025Mar 2026Jun 2026
Promoters606060
FIIs7.997.547.52
DIIs9.45109.43
Public232323
No. of Shareholders31,91433,73843,254

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +144.4% (₹628.20 → ₹1,535.40)Brick size ₹65.80 (fixed)Bricks 21
₹1,000₹1,535Feb '26Jul '26Oct '26
Price moved up one brickPrice moved down one brickLast close ₹1,535.40 on 8 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

-35.00inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

R&D as % of revenue

10.90pct

2026-06-30

FY revenue / permanent employees + workers, same basis (calc)

1,01,24,667inr

2026-03-31

News

News and filings about Rubicon Research Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • excipients
  • packaging materials

Makes products for

  • Select customers in Australia
  • Select customers in India
  • Select customers in New Zealand

Sells to

  • US drug wholesalers (McKesson, Cencora, Cardinal Health - 3 majors handling >90% of US wholesale drug distribution) · Branded specialty & generic prescription / OTC formulations (350+ SKUs); 3 wholesalers are…

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE506V01022

Plants

  • Ambernath manufacturing facility · Ambernath, Maharashtra
  • Pithampur SEZ manufacturing facility · Pithampur, Madhya Pradesh
  • Satara manufacturing facility · Satara, Maharashtra

News impact

Big market events that reach Rubicon Research Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

7 Aug 2026unspecified₹1.5

Splits, bonuses & buybacks

  • daily-prices repair: 1 rows from NSE's archive (replace 0, delete 0, insert 1), 2026-02-01..2026-02-01 (docs/flat_day_repair.md)1× · 1 Feb 2026

Bulk & block deals

DateWhoBought / soldSharesPrice
26 Aug 2026ARANDA INVESTMENTS PTE. LTD.BUY8,43,372₹1,660.00
26 Aug 2026GENERAL ATLANTIC SINGAPORE RR PTE LTDSELL8,43,372₹1,660.00

Insider trades

DisclosedWhoTypeSharesValue ₹ Cr
15 Sep 2026GIRISH SUBRAMANIAM IYER · EmployeeSELL3,0000.55
15 Sep 2026GIRISH SUBRAMANIAM IYER · EmployeeSELL1,5000.27
15 Sep 2026GIRISH SUBRAMANIAM IYER · EmployeeSELL1,2960.23
15 Sep 2026GIRISH SUBRAMANIAM IYER · EmployeeSELL1,0000.18
4 Sep 2026Vinayak Sawant · EmployeeSELL1,1000.20
28 Aug 2026General Atlantic Singapore RR Pte Ltd · PromoterSELL1,38,53,0732,299.61
28 Aug 2026General Atlantic Singapore RR Pte Ltd · PromoterSELL1,46,92725.42
25 Aug 2026Sanjay Renapurkar · EmployeeSELL4,0000.70
25 Aug 2026Sanjay Renapurkar · EmployeeSELL2,0000.36
21 Aug 2026Sarabjit Singh · EmployeeSELL35,0000.00

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.